Sequent Scientific Limited
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was former… Read more
Sequent Scientific Limited (SEQUENT) - Total Assets
Latest total assets as of September 2025: ₹17.26 Billion INR
Based on the latest financial reports, Sequent Scientific Limited (SEQUENT) holds total assets worth ₹17.26 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sequent Scientific Limited - Total Assets Trend (2006–2025)
This chart illustrates how Sequent Scientific Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sequent Scientific Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Sequent Scientific Limited's total assets of ₹17.26 Billion consist of 54.5% current assets and 45.5% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 4.3% |
| Accounts Receivable | ₹3.63 Billion | 22.7% |
| Inventory | ₹3.85 Billion | 24.1% |
| Property, Plant & Equipment | ₹2.99 Billion | 18.7% |
| Intangible Assets | ₹534.50 Million | 3.3% |
| Goodwill | ₹2.49 Billion | 15.5% |
Asset Composition Trend (2006–2025)
This chart illustrates how Sequent Scientific Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sequent Scientific Limited's current assets represent 54.5% of total assets in 2025, an increase from 52.5% in 2006.
- Cash Position: Cash and equivalents constituted 4.3% of total assets in 2025, up from 3.3% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is inventory at 24.1% of total assets.
Sequent Scientific Limited Competitors by Total Assets
Key competitors of Sequent Scientific Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Sequent Scientific Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Sequent Scientific Limited generates 0.97x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Sequent Scientific Limited generates $ 1.37 in net profit.
Sequent Scientific Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.91 | 1.70 | 1.45 |
| Quick Ratio | 1.08 | 0.96 | 1.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹4.57 Billion | ₹ 3.40 Billion | ₹ 2.79 Billion |
Sequent Scientific Limited - Advanced Valuation Insights
This section examines the relationship between Sequent Scientific Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.02 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | ₹16.02 Billion |
| Market Capitalization | $276.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sequent Scientific Limited's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Sequent Scientific Limited's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Sequent Scientific Limited (2006–2025)
The table below shows the annual total assets of Sequent Scientific Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹16.02 Billion | +4.00% |
| 2024-03-31 | ₹15.40 Billion | +0.74% |
| 2023-03-31 | ₹15.29 Billion | +5.39% |
| 2022-03-31 | ₹14.51 Billion | +4.19% |
| 2021-03-31 | ₹13.93 Billion | -4.79% |
| 2020-03-31 | ₹14.63 Billion | +5.39% |
| 2019-03-31 | ₹13.88 Billion | +3.36% |
| 2018-03-31 | ₹13.43 Billion | -29.50% |
| 2017-03-31 | ₹19.05 Billion | +24.64% |
| 2016-03-31 | ₹15.28 Billion | +68.35% |
| 2015-03-31 | ₹9.08 Billion | +45.76% |
| 2014-03-31 | ₹6.23 Billion | +6.22% |
| 2013-03-31 | ₹5.86 Billion | +7.11% |
| 2012-03-31 | ₹5.47 Billion | +21.68% |
| 2011-03-31 | ₹4.50 Billion | +17.76% |
| 2010-03-31 | ₹3.82 Billion | +49.49% |
| 2009-03-31 | ₹2.56 Billion | +154.66% |
| 2008-03-31 | ₹1.00 Billion | +101.37% |
| 2007-03-31 | ₹498.25 Million | +81.44% |
| 2006-03-31 | ₹274.60 Million | -- |